Evelo Biosciences Analyst Ratings
Evelo Biosciences Analyst Ratings
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $4.00 to $2.00. The current price Evelo Biosciences (EVLO) is trading at is $0.83, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/15/2023 | 141.37% | Morgan Stanley | $4 → $2 | Maintains | Equal-Weight |
| 11/16/2022 | 201.71% | Chardan Capital | → $2.5 | Downgrades | Buy → Neutral |
| 09/09/2022 | 382.74% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/24/2022 | 503.43% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | 503.43% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 4908.45% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 1348.23% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 4486.05% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 3279.19% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 1468.91% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 2072.34% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 1589.6% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 3158.51% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | 624.11% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 865.48% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 2434.4% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | 624.11% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 2072.34% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 1106.85% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
| 10/12/2018 | 3520.56% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 10/11/2018 | 3520.56% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 06/04/2018 | 3399.88% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 06/04/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 06/04/2018 | 2917.14% | JMP Securities | → $25 | Initiates Coverage On | → Outperform |
| 06/04/2018 | 3037.82% | BMO Capital | → $26 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 02/15/2023 | 141.37% | 摩根士丹利 | $4 → $2 | 维护 | 等重 |
| 11/16/2022 | 201.71% | 查尔丹资本 | → $2.5 | 评级下调 | 购买→中性 |
| 09/09/2022 | 382.74% | 摩根士丹利 | $5 → $4 | 维护 | 等重 |
| 08/24/2022 | 503.43% | 摩根士丹利 | $6 → $5 | 维护 | 等重 |
| 08/15/2022 | 503.43% | 查尔丹资本 | $12 → $5 | 维护 | 买 |
| 11/02/2021 | 4908.45% | JMP证券 | $44 → $41.5 | 维护 | 市场表现强于大盘 |
| 11/01/2021 | 1348.23% | 查尔丹资本 | → $12 | 升级 | 中性→购买 |
| 06/23/2021 | 4486.05% | JMP证券 | $36 → $38 | 维护 | 市场表现强于大盘 |
| 06/23/2021 | 3279.19% | 康托·菲茨杰拉德 | → $28 | 开始承保 | →超重 |
| 05/03/2021 | 1468.91% | 摩根士丹利 | $14 → $13 | 维护 | 等重 |
| 04/12/2021 | 2072.34% | 杰富瑞 | $11 → $18 | 升级 | 持有→购买 |
| 01/19/2021 | 1589.6% | 摩根士丹利 | $6 → $14 | 维护 | 等重 |
| 12/23/2020 | 3158.51% | JMP证券 | → $27 | 开始承保 | →跑赢大盘 |
| 11/11/2020 | 624.11% | 摩根士丹利 | $8 → $6 | 维护 | 等重 |
| 05/21/2020 | 865.48% | 摩根士丹利 | → $8 | 评级下调 | 超重→等重 |
| 05/12/2020 | 2434.4% | 蒙特利尔银行资本 | $24 → $21 | 维护 | 跑赢大盘 |
| 05/12/2020 | 624.11% | 杰富瑞 | $18 → $6 | 评级下调 | 购买→Hold |
| 04/30/2019 | 2072.34% | 杰富瑞 | → $18 | 开始承保 | →购买 |
| 01/29/2019 | 1106.85% | 查尔丹资本 | → $10 | 开始承保 | →中性 |
| 10/12/2018 | 3520.56% | 摩根士丹利 | $29 → $30 | 维护 | 超重 |
| 10/11/2018 | 3520.56% | 摩根士丹利 | $29 → $30 | 维护 | 超重 |
| 06/04/2018 | 3399.88% | 摩根士丹利 | → $29 | 开始承保 | →超重 |
| 06/04/2018 | — | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 06/04/2018 | 2917.14% | JMP证券 | → $25 | 开始承保 | →跑赢大盘 |
| 06/04/2018 | 3037.82% | 蒙特利尔银行资本 | → $26 | 开始承保 | →跑赢大盘 |
What is the target price for Evelo Biosciences (EVLO)?
Evelo Biosciences(EVLO)的目标价格是多少？
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by Morgan Stanley on February 15, 2023. The analyst firm set a price target for $2.00 expecting EVLO to rise to within 12 months (a possible 141.37% upside). 5 analyst firms have reported ratings in the last year.
纳斯达克(EVLO)最新目标价由摩根士丹利于2023年2月15日报道。这家分析公司将目标价定为2美元，预计EVLO将在12个月内升至(可能上涨141.37%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Evelo Biosciences (EVLO)?
Evelo Biosciences(EVLO)的最新分析师评级是多少？
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by Morgan Stanley, and Evelo Biosciences maintained their equal-weight rating.
伊维洛生物科学公司(纳斯达克代码：EVLO)的最新分析师评级由摩根士丹利提供，伊维洛生物科学公司维持其同等权重评级。
When is the next analyst rating going to be posted or updated for Evelo Biosciences (EVLO)?
Evelo Biosciences(EVLO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on February 15, 2023 so you should expect the next rating to be made available sometime around February 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Evelo Biosciences的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Evelo Bioscience的上一次评级是在2023年2月15日提交的，所以你应该预计下一次评级将在2024年2月15日左右提供。
Is the Analyst Rating Evelo Biosciences (EVLO) correct?
分析师对Evelo Biosciences(EVLO)的评级正确吗？
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $4.00 to $2.00. The current price Evelo Biosciences (EVLO) is trading at is $0.83, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Evelo Biosciences(EVLO)评级保持不变，目标价在4.00美元至2.00美元之间。Evelo Biosciences(EVLO)目前的交易价格为0.83美元，超出了分析师的预测区间。
